IPP Bureau
EU green light to IntraBio’s AQNEURSA for rare neurological disease Niemann-Pick Type C
By IPP Bureau - January 28, 2026
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Hester receives manufacturing license for inactivated avian influenza vaccine for poultry
By IPP Bureau - January 27, 2026
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
By IPP Bureau - January 25, 2026
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Amway India launches ‘Beyond Biotin’ Nutrilite Biotin C Plus to support skin, hair, nail health
By IPP Bureau - January 24, 2026
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
Yugap Wellness bolsters scientific leadership with Dr Satish Singh appointment
By IPP Bureau - January 24, 2026
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report
By IPP Bureau - January 24, 2026
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
By IPP Bureau - January 24, 2026
Company to launch product after the expiry of semaglutide patent in India
Lupin receives highest ESG rating from CDP for climate change and water security
By IPP Bureau - January 24, 2026
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
.jpg "Cipla reports consolidated PAT of Rs. 675.80 Cr")
Cipla reports consolidated PAT of Rs. 675.80 Cr
By IPP Bureau - January 24, 2026
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Laurus Labs reports consolidated Q3 net profit of Rs. 251.66 Cr
By IPP Bureau - January 24, 2026
Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025
Jagsonpal Pharmaceuticals posts Q3 FY26 profit at Rs. 10.95 Cr
By IPP Bureau - January 24, 2026
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
Akums bags key EU GMP certifications for 2 Haridwar plants
By IPP Bureau - January 24, 2026
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Telangana unveils ambitious next-gen Life Sciences Policy at Davos
By IPP Bureau - January 24, 2026
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Novo Medi Sciences unveils India’s next-generation varicella vaccine NEXIPOX PLUS
By IPP Bureau - January 24, 2026
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
